Is Sermorelin + Ipamorelin approved as a medicine, and where?

The regulatory review of Sermorelin + Ipamorelin is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

What is Sermorelin + Ipamorelin studied for?

Research has examined Component-level GHRH and GHS-R1a pharmacology (see linked monographs). Being studied for an area does not mean it is proven or approved for it.

Does Sermorelin + Ipamorelin have human clinical trials?

The evidence review of Sermorelin + Ipamorelin is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Peptide Blends

Sermorelin + Ipamorelin

Sermorelin / Ipamorelin stack; Sermorelin and Ipamorelin blend

2 min read · Updated October 7, 2026 · 6 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

In brief · TL;DR

Source record — verification pending

GHRH(1-29) + selective ghrelin-receptor agonist stack with zero combo RCTs and zero CT.gov pair studies. Evidence is component-wise only. Do not read historical Geref approval as current marketing authorisation for the stack. No dose.

Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.

Trade stack: sermorelin (GHRH 1-29) + ipamorelin (GHS-R1a) — not a covalent conjugate
No controlled human combination RCT; CT.gov pair search empty (2026-10-07 dossier)
Sermorelin: historically FDA-approved as Geref (discontinued ~2008; approval withdrawn 2009) — not current anti-aging approval
Ipamorelin: never approved; ileus RCT missed primary endpoint
Compare with CJC-1295 + ipamorelin stack — different GHRH arm, same combo-data void

↓ Read the full referenced entry below

Sermorelin + ipamorelin is a common compounding/vendor stack pairing GHRH(1-29) with a selective GHS-R1a agonist — not a new molecule. No controlled human combination study was identified. Sermorelin has historical US approval (Geref, discontinued); ipamorelin was never approved.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents5

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). Visible but noindexed. Editorial lane: scope-review-blend.

No controlled human combination data

No published controlled study was identified in which sermorelin and ipamorelin were given together with a measured clinical or pharmacologic outcome. CT.gov pair search: 0. Vendor “GH stack” synergy claims are not evidence.

Section 1 of 5What this stack means

What this stack means

Component	Role	Existing monograph
Sermorelin	GHRH(1-29)-NH₂ — shortest fully active GHRH fragment	Approved medicine historically (US Geref); brand discontinued
Ipamorelin	Selective GHS-R1a / ghrelin-receptor agonist	Limited/early human data — not approved

There is no CAS for the blend. Mechanistic rationale (GHRH receptor + GHS-R1a → GH) is a hypothesis, not proof for this product.

Section 2 of 5Component evidence (pointer only)

Component evidence (pointer only)

Sermorelin

Stimulates endogenous pulsatile GH. Historical US product Geref covered diagnostic and paediatric GHD contexts; brand discontinued ~2008 and FDA withdrew approval in 2009 not for a new safety signal in the usual framing — still not a current authorisation for anti-aging or body recomposition. Plasma half-life is very short (minutes IV per available SmPC framing). WADA: GHRH analogues are prohibited (S2-related) — follow the current list.

Ipamorelin

Selective GH release with minimal ACTH/cortisol in early studies (Raun 1998). Terminal half-life ~2 h (Gobburu 1999). Only published efficacy RCT (post-op ileus, Beck 2014) missed its primary endpoint. Never approved; WADA S2-related.

Versus CJC-1295 + Ipamorelin

	Sermorelin + ipa	CJC-1295 + ipa
GHRH arm	Native-length fragment, short-acting	DAC (long) or no-DAC/Mod GRF (short) — vendor confusion
Combo RCT	None	None
Extra trap	“Formerly approved” over-read as current legality/efficacy	Teichman 2006 borrowed onto no-DAC blends

Section 3 of 5Claims vs evidence

Claims vs evidence

Claim	Assessment
Stack = GHRH(1-29) + GHS-R1a agonist	Partially supported as trade definition
Proven synergistic GH for the pair	Not verified
Sermorelin “FDA approved” today as a marketed product	False — historical only
Ipamorelin approved	False
Own CAS; fixed nightly protocol; WADA-allowed	False / reject

Section 4 of 5Related pages

Section 5 of 5What this page intentionally omits

What this page intentionally omits

Any dose, nightly protocol, or reconstitution schedule
Synergy or body-recomposition figures
Treating historical Geref approval as current stack authorisation

References6

References

1.
Sermorelin — a review of its use source
2.
Ipamorelin — selective GH secretagogue (Raun 1998) source
3.
Ipamorelin postoperative ileus RCT — primary endpoint not met source
4.
PeptideInfo — Sermorelin source
5.
PeptideInfo — Ipamorelin source
6.
PeptideInfo — CJC-1295 + Ipamorelin source

Frequently asked questions4

Frequently asked questions

What is Sermorelin + Ipamorelin?: Sermorelin + ipamorelin is a common compounding/vendor stack pairing GHRH(1-29) with a selective GHS-R1a agonist — not a new molecule. No controlled human combination study was identified. Sermorelin has historical US approval (Geref, discontinued); ipamorelin was never approved.
Is Sermorelin + Ipamorelin approved as a medicine, and where?: The regulatory review of Sermorelin + Ipamorelin is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is Sermorelin + Ipamorelin studied for?: Research has examined Component-level GHRH and GHS-R1a pharmacology (see linked monographs). Being studied for an area does not mean it is proven or approved for it.
Does Sermorelin + Ipamorelin have human clinical trials?: The evidence review of Sermorelin + Ipamorelin is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of Sermorelin + Ipamorelin is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.

References

Frequently asked questions

Related in Peptide Blends